Clinical Trial

Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this Phase II clinical trial is to establish the safety and effectiveness of trametinib, a targeted therapy, for the treatment of newly or recently diagnosed Langerhans Cell Histiocytosis (LCH) among pediatric patients.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-08-30; most recent amendment 2026-04-01.
Trial Details
NCT Number NCT06582745
Lead Sponsor Cook Children's Health Care System
Conditions Langerhans Cell Histiocytosis
Enrollment 75 participants
Start Date 2024-06-24
Primary Completion 2039-06 (estimated)
Study Completion 2039-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-07